Details
| Stereochemistry | UNKNOWN |
| Molecular Formula | C27H28N2O7 |
| Molecular Weight | 492.5204 |
| Optical Activity | ( + ) |
| Additional Stereochemistry | Yes |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COCCOC(=O)C1=C(C)NC(C)=C(C1C2=CC(=CC=C2)[N+]([O-])=O)C(=O)OC\C=C\C3=CC=CC=C3
InChI
InChIKey=KJEBULYHNRNJTE-DHZHZOJOSA-N
InChI=1S/C27H28N2O7/c1-18-23(26(30)35-14-8-11-20-9-5-4-6-10-20)25(21-12-7-13-22(17-21)29(32)33)24(19(2)28-18)27(31)36-16-15-34-3/h4-13,17,25,28H,14-16H2,1-3H3/b11-8+
| Molecular Formula | C27H28N2O7 |
| Molecular Weight | 492.5204 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 1 |
| Optical Activity | ( + / - ) |
DescriptionCurator's Comment: Description was created based on several sources, including
http://www.nevapress.com/cdr/full/17/4/341.pdf | https://www.ncbi.nlm.nih.gov/pubmed/19426250
Curator's Comment: Description was created based on several sources, including
http://www.nevapress.com/cdr/full/17/4/341.pdf | https://www.ncbi.nlm.nih.gov/pubmed/19426250
Cilnidipine (FRC-8653) is a dihydropyridine (DHP) type of calcium channel antagonist. The L-type Ca2+ channel blockade by cilnidipine affects predominantly vascular smooth muscle, thereby producing vasodilation of peripheral resistance vessels and coronary arteries. The blockade of N-type Ca2+ channels affects predominantly peripheral nerve endings of sympathetic neurons, thereby dilating blood vessels by lowering plasma catecholamine levels. Furthermore, renoprotective and neuroprotective effects as well as cardioprotective action of cilnidipine have been demonstrated in clinical practice or animal examinations. Cilnidipine was originated by Fuji & Rebio Pharmaceutical Co., Ltd. and developed jointly with Ajinomoto for the treatment of hypertension. Cilnidipine has been launched in Japan.
Approval Year
Sample Use Guides
Normally once daily 5 to 10 mg of cilnidipine after breakfast orally for
adult patient. The dose can be increased or reduced according to the
age and symptoms. If the above dose is not effective enough, the dose
can be increased to 20 mg once daily. For severe hypertension, 10 to 20
mg of cilnidipine orally once daily after breakfast.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:18:07 UTC 2023
by
admin
on
Sat Dec 16 10:18:07 UTC 2023
|
| Record UNII |
S85436ZG85
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
S85436ZG85
Created by
admin on Sat Dec 16 10:18:07 UTC 2023 , Edited by admin on Sat Dec 16 10:18:07 UTC 2023
|
PRIMARY | |||
|
118934-77-3
Created by
admin on Sat Dec 16 10:18:07 UTC 2023 , Edited by admin on Sat Dec 16 10:18:07 UTC 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
5282138
Created by
admin on Sat Dec 16 10:18:07 UTC 2023 , Edited by admin on Sat Dec 16 10:18:07 UTC 2023
|
PRIMARY | |||
|
132338-87-5
Created by
admin on Sat Dec 16 10:18:07 UTC 2023 , Edited by admin on Sat Dec 16 10:18:07 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
RACEMATE -> ENANTIOMER |
